CStone grants Arrotex exclusive rights to commercialise Sugemalimab in Australia, New Zealand
CStone Pharmaceuticals (HKEX: 2616) has signed an exclusive commercialisation agreement with Arrotex, granting rights to its oncology therapy Sugemalimab across the Australia and New Zealand markets. SUZHOU, China, June 25, 2026 /PRNewswire/ -- …